| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
|
Hypertens Res
|
2010
|
2.09
|
|
2
|
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients.
|
Hypertens Res
|
2010
|
1.54
|
|
3
|
Irbesartan and hydrochlorothiazide association in the treatment of hypertension.
|
Curr Vasc Pharmacol
|
2009
|
1.40
|
|
4
|
Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
|
Endothelium
|
2006
|
1.27
|
|
5
|
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
|
Metabolism
|
2009
|
1.04
|
|
6
|
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
|
Clin Ther
|
2006
|
1.02
|
|
7
|
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
|
Hypertens Res
|
2007
|
0.95
|
|
8
|
Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study.
|
Diabetes Technol Ther
|
2009
|
0.93
|
|
9
|
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
|
Am J Hypertens
|
2008
|
0.90
|
|
10
|
Oral fat load effects on inflammation and endothelial stress markers in healthy subjects.
|
Heart Vessels
|
2009
|
0.88
|
|
11
|
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia.
|
Clin Invest Med
|
2009
|
0.88
|
|
12
|
LIN7 regulates the filopodium- and neurite-promoting activity of IRSp53.
|
J Cell Sci
|
2012
|
0.88
|
|
13
|
Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
|
Clin Ther
|
2007
|
0.87
|
|
14
|
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients.
|
Curr Med Res Opin
|
2009
|
0.87
|
|
15
|
Home mechanical ventilation in children: retrospective survey of a pediatric population.
|
Pediatr Int
|
2007
|
0.86
|
|
16
|
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
|
Clin Ther
|
2005
|
0.83
|
|
17
|
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
|
Hypertens Res
|
2006
|
0.83
|
|
18
|
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load.
|
Eur J Pharmacol
|
2010
|
0.83
|
|
19
|
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
|
Endocr J
|
2010
|
0.83
|
|
20
|
Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects.
|
Microvasc Res
|
2010
|
0.82
|
|
21
|
Sequential unsymmetrical aryl coupling of o-substituted aryl iodides with o-bromophenols and reaction with olefins: palladium-catalyzed synthesis of 6H-dibenzopyran derivatives.
|
Org Lett
|
2006
|
0.81
|
|
22
|
Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
|
Intern Med
|
2007
|
0.81
|
|
23
|
Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects.
|
Microvasc Res
|
2010
|
0.81
|
|
24
|
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.
|
Hypertens Res
|
2005
|
0.80
|
|
25
|
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
|
Curr Med Res Opin
|
2009
|
0.80
|
|
26
|
Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
|
Expert Opin Pharmacother
|
2010
|
0.80
|
|
27
|
Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients.
|
Intern Med
|
2010
|
0.79
|
|
28
|
Candesartan effect on inflammation in hypertension.
|
Hypertens Res
|
2010
|
0.79
|
|
29
|
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
|
Fundam Clin Pharmacol
|
2010
|
0.78
|
|
30
|
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients.
|
Metabolism
|
2010
|
0.78
|
|
31
|
Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment.
|
Biomed Pharmacother
|
2009
|
0.78
|
|
32
|
Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer.
|
Mini Rev Med Chem
|
2015
|
0.78
|
|
33
|
Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI).
|
Endocr J
|
2009
|
0.78
|
|
34
|
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
|
Pharmacotherapy
|
2005
|
0.77
|
|
35
|
Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome.
|
Clin Exp Hypertens
|
2010
|
0.77
|
|
36
|
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
|
Metabolism
|
2008
|
0.77
|
|
37
|
Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance.
|
Clin Drug Investig
|
2006
|
0.77
|
|
38
|
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
|
Arch Med Res
|
2008
|
0.77
|
|
39
|
The POF1B candidate gene for premature ovarian failure regulates epithelial polarity.
|
J Cell Sci
|
2011
|
0.76
|
|
40
|
Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
|
J Pharm Pharm Sci
|
2010
|
0.76
|
|
41
|
Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
|
Intern Med
|
2009
|
0.76
|
|
42
|
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
|
Metabolism
|
2009
|
0.75
|
|
43
|
Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months.
|
J Clin Pathol
|
2006
|
0.75
|
|
44
|
Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension.
|
J Cardiovasc Pharmacol
|
2006
|
0.75
|